$COGT News

Piper Sandler Maintains Overweight on Cogent Biosciences, Raises Price Target to $55

Guggenheim Maintains Buy on Cogent Biosciences, Raises Price Target to $52

Cogent Biosciences Files Prospectus for At-The-Market Offering Of Up To $400M In Common Stock

Cogent Biosciences Q2 EPS $(0.52) Beats $(0.57) Estimate

If You Invested $100 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today

Cogent Biosciences (NASDAQ:COGT) Shows Perfect Breakout Setup with Top Technical Strength

Cogent Biosciences Files New Drug Application To FDA For Bezuclastinib In Advanced Systemic Mastocytosis

Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage

Cogent Biosciences, Inc. (COGT) Presents at European Hematology Association (EHA) 2026 Congress - Slideshow

Cogent Biosciences' Potential Rare Blood Disease Treatment Meets Endpoints in Clinical Trial

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress

Cogent Biosciences To Present Preclinical Data From Its Novel JAK2 V617F Mutant-Selective Inhibitor At The 2026 European Hematology Association Congress, June 11-14

How Investors May Respond To Cogent Biosciences (COGT) Priority Review For Bezuclastinib GIST Regimen

Is Cogent Biosciences, Inc. (COGT) A Good Stock To Buy Now?

Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST

Cogent Biosciences Says FDA Accepts NDA For Bezuclastinib In Combination With Sunitinib For Patients With GIST With PDUFA Target Action Date Of November 30

Assessing Cogent Biosciences (COGT) Valuation After A Strong Year And Recent Share Price Pullback